WESPAC Advisors’s Biogen BIIB Stock Holding History

WESPAC Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1,587	Closed	-$670K	–	117
2015 Q1	$670K	Buy	+1,587	New	+$625K	0.51%	71

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

WESPAC Advisors's BIIB Position: Q2 2015 in Review

WESPAC Advisors sold out of Biogen (BIIB) in Q2 2015, closing a stake of 1,587 shares — an estimated $670K sold.

WESPAC Advisors first reported a position in BIIB in Q1 2015 and held it in 1 quarter. The position peaked at $670K in Q1 2015. 974 funds tracked by Wall St. Rank hold BIIB as of Q2 2015.

WESPAC Advisors reported no remaining Biogen position as of Q2 2015 after selling out during the quarter.
WESPAC Advisors sold 1,587 Biogen shares in Q2 2015, an estimated $670K.
WESPAC Advisors first reported a position in Biogen in Q1 2015 and held it in 1 quarter.
WESPAC Advisors's Biogen position peaked at $670K in Q1 2015.
974 funds tracked by Wall St. Rank held Biogen as of Q2 2015.

Based on WESPAC Advisors's 13F filing for Q2 2015, filed 16 Jul 2015.